RESUMO
Co-treatment of mice infected with different strains of Leishmania donovani with a non-ionic surfactant vesicle formulation of buthionine sulfoximine (BSO-NIV), and sodium stibogluconate (SSG), did not alter indicators of Th1 or Th2 responses but did result in a significant strain-independent up-regulation of IL6 and nitrite levels by stimulated splenocytes from treated mice compared to controls. The efficacy of BSO-NIV/SSG treatment was dependent on the host being able to mount a respiratory burst indicating that macrophages are important in controlling the outcome of treatment. In vitro studies showed that SSG resistance was associated with a greater resistance to killing by activated macrophages, treatment with hydrogen peroxide or potassium antimony tartrate. Longitudinal studies showed that a SSG resistant (SSG-R) strain was more virulent than a SSG susceptible (SSG-S) strain, resulting in significantly higher parasite burdens by 4 months post-infection. These results indicate that SSG exposure may favour the emergence of more virulent strains.
Assuntos
Gluconato de Antimônio e Sódio/farmacologia , Antiprotozoários/farmacologia , Leishmania donovani/efeitos dos fármacos , Leishmania donovani/imunologia , Macrófagos/imunologia , Animais , Tartarato de Antimônio e Potássio/farmacologia , Gluconato de Antimônio e Sódio/uso terapêutico , Antiprotozoários/uso terapêutico , Butionina Sulfoximina/farmacologia , Butionina Sulfoximina/uso terapêutico , Cricetinae , Resistência a Medicamentos , Feminino , Humanos , Peróxido de Hidrogênio/farmacologia , Interleucina-6/análise , Interleucina-6/biossíntese , Leishmania donovani/patogenicidade , Lipopolissacarídeos/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/parasitologia , Masculino , Mesocricetus , Camundongos , Camundongos Endogâmicos BALB C , Nitritos/análise , Nitritos/metabolismo , Baço/química , Baço/parasitologia , VirulênciaRESUMO
Firm diagnosis of visceral leishmaniasis (kala-azar) requires organ aspiration and microscopic examination of tissue specimens. To determine the usefulness of noninvasive diagnosis by strip test detection of anti-K39 immunoglobulin (Ig) G antibody in blood specimens obtained by fingerstick, 143 Indian patients with suspected kala-azar (fever, splenomegaly, anemia) were studied. Of 120 strip test-positive subjects (subjects with presumed kala-azar [group A]), amphotericin B treatment induced clinical cure in 119. Of 23 strip test-negative subjects (subjects presumed to have other diseases [group B]), 16 had other disorders diagnosed at entry, 4 responded to empiric antimalarial therapy, 2 were proven to have kala-azar, and 1 died elsewhere after undergoing splenic aspiration. Six months after treatment ended, all 120 patients in group A and the 18 assessable patients in group B were healthy. In a region in India where visceral infection is prevalent, strip test detection of anti-K39 IgG is a clinically promising diagnostic guide in persons with suspected kala-azar.
Assuntos
Antígenos de Protozoários , Leishmaniose Visceral/diagnóstico , Proteínas de Protozoários/análise , Adolescente , Adulto , Anticorpos/análise , Biomarcadores/análise , Técnicas e Procedimentos Diagnósticos , Feminino , Seguimentos , Humanos , Índia/epidemiologia , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/imunologia , Masculino , Pesquisa , Resultado do TratamentoRESUMO
Stored sera from 429 Indian subjects were assayed to extend the analysis of the accuracy of immunochromatographic strip-test detection of anti-K39 antibody in the non-invasive diagnosis of visceral leishmaniasis (VL). All 225 samples from patients with proven Leishmania infection tested positive [estimated sensitivity = 100%; 95% confidence interval (CI)=98%-100%]. Sera from 99 of the 100 symptomatic patients with other diseases were non-reactive (estimated specificity = 99%; CI = 94%-100%). However, samples from 13 of the 104 apparently healthy controls showed positive strip-test results (estimated specificity = 88%; CI = 79%-93%), yielding an overall specificity of 93% (190/204; CI = 88%-96%). If applied in a practical clinical setting (on symptomatic patients in whom active VL is suspected and other common infections have been excluded), strip testing of serum for anti-K39 antibody should be both sensitive and specific for diagnosing VL in India.
Assuntos
Anticorpos Antiprotozoários/sangue , Antígenos de Protozoários/imunologia , Leishmania/imunologia , Leishmaniose Visceral/diagnóstico , Proteínas de Protozoários/imunologia , Adolescente , Adulto , Animais , Feminino , Humanos , Masculino , Parasitologia/métodos , Fitas Reagentes , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
In experimental visceral leishmaniasis in normal mice (BALB/c, C57BL/6) acquired resistance to Leishmania donovani, a protozoan which targets tissue macrophages, depends upon T cells, Th1 cell-type cytokine generation and activated mononuclear phagocytes. In the intact host, initial control and eventual resolution of L. donovani hepatic infection in normal mice is expressed by and accomplished within well-formed, mature tissue granulomas. In the liver, these immunologically active, inflammatory structures are assembled around a core of fused, parasitized resident macrophages (Kupffer cells) which come to be encircled by both cytokine-secreting T cells and influxing leishmanicidal blood monocytes. This pro-host defense granuloma structure-function relationship, in which histologically mature granulomas provide the microenvironment for intracellular L. donovani killing, however, is only one of seven which have been identified through experimental modifications in this model. This report reviews these structure-function relationships and illustrates the broad spectrum of additional possible responses. These responses range from structurally intact granulomas which provide no antileishmanial function (the 'ineffective' granuloma), to enlarged granulomas which show enhanced parasite killing (the 'hypertrophied' granuloma), to effective antileishmanial activity in the absence of any tissue reaction (the 'invisible' granuloma).
Assuntos
Granuloma/imunologia , Leishmania donovani/imunologia , Leishmaniose Visceral/imunologia , Hepatopatias/imunologia , Animais , Citocinas/imunologia , Molécula 1 de Adesão Intercelular/imunologia , Células de Kupffer/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Monócitos/imunologia , Linfócitos T/imunologia , Células Th1/imunologiaRESUMO
OBJECTIVE: To test short course, low dose liposomal amphotericin B as single or daily infusion treatment in Indian visceral leishmaniasis (kala-azar). DESIGN: Randomised, open label study. SETTING: Inpatient unit for leishmaniasis in Bihar, India. PARTICIPANTS: 91 adults and children with splenic aspirate positive for infection. INTERVENTIONS: Total dose of 5 mg/kg of liposomal amphotericin B given as a single infusion (n=46) or as once daily infusions of 1 mg/kg for five days (n=45). MAIN OUTCOME MEASURES: Clinical and parasitological cure assessed 14 days after treatment and long term definitive cure (healthy, no relapse) at six months. RESULTS: All but one person in each group had an initial apparent cure. During six months of follow up, three patients in the single dose group and two in the five dose group relapsed. Complete response (definitive cure) was therefore achieved in 84 of 91 subjects (92%): 42 of 46 patients in the single dose group (91%, 95% confidence interval 79% to 98%) and 42 of 45 in the five dose group (93%, 82% to 99%). Response rates in the two groups were not significantly different. CONCLUSION: Low dose liposomal amphotericin B (5 mg/kg), given either as a five day course or as a single infusion, seems to be effective for visceral leishmaniasis and warrants further testing.
Assuntos
Anfotericina B/administração & dosagem , Antiprotozoários/administração & dosagem , Leishmaniose Visceral/tratamento farmacológico , Adolescente , Adulto , Anfotericina B/efeitos adversos , Anfotericina B/uso terapêutico , Antiprotozoários/efeitos adversos , Antiprotozoários/uso terapêutico , Criança , Esquema de Medicação , Feminino , Humanos , Infusões Intravenosas , Lipossomos , Masculino , Projetos Piloto , Recidiva , Resultado do TratamentoRESUMO
In experimental visceral leishmaniasis, interleukin (IL)-12 initiates control over Leishmania donovani via Th1 cell activation, interferon (IFN)-gamma secretion, and granuloma formation. Because the leishmanicidal effect of conventional therapy, pentavalent antimony (Sb), also requires T cells and endogenous IFN-gamma, we tested IL-12 as a determinant of host responsiveness to chemotherapy. L. donovani-challenged IL-12p35 gene knockout (KO) mice permitted uncontrolled hepatic infection and failed to respond to Sb. In contrast, 96% of liver parasites in KO mice were killed by amphotericin B, which acts independently of immune responses. Exogenous IL-12 combined with Sb was tested in normal mice: low-dose Sb was converted from weakly to strongly leishmanicidal, and a no-effect Sb dose was converted to approximately 100% leishmanistatic. IL-12 plus Sb synergism in normal mice was IFN-gamma dependent; however, IL-12 also increased responsiveness to Sb in IFN-gamma KO mice. Thus, IL-12 regulates host IFN-gamma-dependent and -independent responses that permit and/or enhance the leishmanicidal activity of Sb.
Assuntos
Interleucina-12/fisiologia , Leishmaniose Visceral/tratamento farmacológico , Animais , Antimônio/uso terapêutico , Interferon gama/fisiologia , Interleucina-4/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos KnockoutRESUMO
In India, 320 patients with visceral leishmaniasis (209 in the state of Bihar and 11 in the neighboring state of Uttar Pradesh) received identical pentavalent antimony (Sb) treatment. Sb induced long-term cure in 35% (95% confidence interval [CI], 28%-42%) of those in Bihar versus 86% (95% CI, 79%-93%) of those in Uttar Pradesh. In Bihar, the center of the Indian epidemic, traditional Sb treatment should be abandoned.
Assuntos
Gluconato de Antimônio e Sódio/uso terapêutico , Antiprotozoários/uso terapêutico , Surtos de Doenças , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/epidemiologia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Índia/epidemiologia , Lactente , Masculino , Pessoa de Meia-Idade , Falha de TratamentoRESUMO
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.
Assuntos
Antiprotozoários/administração & dosagem , Leishmaniose Visceral/tratamento farmacológico , Fosforilcolina/análogos & derivados , Administração Oral , Adulto , Antiprotozoários/efeitos adversos , Diarreia/induzido quimicamente , Esquema de Medicação , Feminino , Humanos , Masculino , Fosforilcolina/administração & dosagem , Fosforilcolina/efeitos adversos , Vômito/induzido quimicamenteRESUMO
Tumor necrosis factor (TNF)-deficient mice were challenged with Leishmania donovani to characterize TNF in the response of visceral intracellular infection to antileishmanial chemotherapy. In wild-type controls (i) liver infection peaked at week 2 and resolved, (ii) discrete liver granulomas developed at weeks 2 to 4 and involuted, and (iii) leishmanicidal responses to antimony (Sb), amphotericin B (AmB), and miltefosine were intact. In TNF knockout (KO) mice (i) initial liver infection was unrestrained, plateaued, and then declined somewhat by week 6, (ii) an absent early granulomatous reaction abruptly accelerated with striking tissue inflammation, widespread hepatic necrosis, and 100% mortality by week 10, and (iii) while the initial response to AmB and miltefosine was intact, killing induced by Sb therapy was reduced by >50%. Although initial AmB treatment during weeks 2 to 3 killed 98% of liver parasites, 75% of AmB-treated KO mice subsequently relapsed and died by week 12; however, additional maintenance AmB preserved long-term survival. These results for a model of visceral infection indicate that endogenous TNF is required early on to control intracellular L. donovani, support granuloma development, and mediate optimal initial effects of Sb and prevent relapse after ordinarily curative AmB treatment. A compensatory, TNF-independent antileishmanial mechanism developed in TNF KO mice; however, its effect was uncontrolled fatal inflammation. Chemotherapeutic elimination of the parasite stimulus reversed the hyperinflammatory response and preserved survival.
Assuntos
Leishmania donovani , Leishmaniose Visceral/imunologia , Fator de Necrose Tumoral alfa/fisiologia , Anfotericina B/uso terapêutico , Animais , Feminino , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/mortalidade , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Células Th1/fisiologiaRESUMO
In experimental visceral leishmaniasis, acquired resistance to intracellular Leishmania donovani is Th1 cell cytokine dependent and largely mediated by gamma interferon (IFN-gamma); the same response also permits conventional antimony (Sb) chemotherapy to express its leishmanicidal effect. Since the influxing blood monocyte (which utilizes endothelial cell ICAM-1 for adhesion and tissue entry) is a primary effector target cell for this cytokine mechanism, we tested the monocyte's role in host responsiveness to chemotherapy in mice with ICAM-1 gene disruptions. Mutant animals failed to develop any early granulomatous tissue response in the liver, initially supported high-level visceral parasite replication, and showed no killing after Sb treatment; the leishmanicidal response to a directly acting, alternative chemotherapeutic probe, amphotericin B, was intact. However, mutant mice proceeded to express a compensatory, ICAM-1-independent response leading to mononuclear cell influx and granuloma assembly, control over visceral infection, and the capacity to respond to Sb. Together, these results point to the recruitment of emigrant monocytes and mononuclear cell granuloma formation, mediated by ICAM-1-dependent and -independent pathways, as critical determinants of host responsiveness to conventional antileishmanial chemotherapy.
Assuntos
Granuloma/etiologia , Molécula 1 de Adesão Intercelular/fisiologia , Leishmaniose Visceral/imunologia , Leucócitos Mononucleares/fisiologia , Animais , Antimônio/uso terapêutico , Movimento Celular , Interferon gama/biossíntese , Leishmaniose Visceral/tratamento farmacológico , Camundongos , Camundongos Endogâmicos C57BL , Monócitos/fisiologia , Linfócitos T/fisiologiaRESUMO
T-cell-deficient nude mice infected with Leishmania donovani were treated with miltefosine and then given either no treatment or intermittent miltefosine. Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine. Miltefosine may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.
Assuntos
Antiprotozoários/uso terapêutico , Leishmaniose Visceral/prevenção & controle , Fosforilcolina/análogos & derivados , Fosforilcolina/uso terapêutico , Linfócitos T/imunologia , Administração Oral , Animais , Modelos Animais de Doenças , Leishmania donovani , Leishmaniose Visceral/imunologia , Leishmaniose Visceral/patologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Prevenção SecundáriaRESUMO
Although short-course therapy with new lipid formulations of amphotericin B represents an advance over lengthy traditional treatments in visceral leishmaniasis (kala-azar), high cost has rendered these agents largely irrelevant in developing countries where the disease is endemic. Therefore, we tested standard amphotericin B deoxycholate mixed with a commercial fat emulsion as short-course treatment for Indian visceral leishmaniasis in Bihar in 1997/98. Seventy children and adults with splenic aspirate-documented infection, 23 of whom had failed prior antimony (Sb) therapy, received 5 alternate-day infusions of 2 mg/kg. Apparent cure, which required a parasite-free splenic aspirate smear, was assessed 20 days after treatment (day 30); definitive cure was determined at 6 months. Other than anticipated infusion-related fever and/or chills, treatment was safe and well tolerated. One patient required dose modification because of mild, reversible renal insufficiency. Sixty-nine patients (98.6%, CI 92.3-100%) had apparent cures; during follow-up, there were 4 treatment failures (relapses, 3; unrelated death, 1), yielding definitive cures in 65 of 70 patients (92.9%, CI 84.1-97.6%). Including retreatment costs for patients in Bihar (who now often fail initial Sb therapy), the final per patient cost of the tested regimen (US $260) was 59% and 43% less than treatment with Sb or conventional amphotericin B alone, respectively. Short-course treatment with amphotericin B-fat emulsion is active, cost-effective treatment for patients with visceral leishmaniasis including those with Sb-unresponsive infection.
Assuntos
Anfotericina B/administração & dosagem , Antiprotozoários/administração & dosagem , Leishmaniose Visceral/tratamento farmacológico , Adolescente , Adulto , Anfotericina B/economia , Antiprotozoários/economia , Criança , Pré-Escolar , Análise Custo-Benefício , Custos de Medicamentos , Emulsões Gordurosas Intravenosas/administração & dosagem , Emulsões Gordurosas Intravenosas/economia , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Masculino , Resultado do TratamentoAssuntos
Medicina Tropical/tendências , Filariose Linfática/diagnóstico , Filariose Linfática/prevenção & controle , Filariose Linfática/terapia , Humanos , Leishmaniose/diagnóstico , Leishmaniose/prevenção & controle , Leishmaniose/terapia , Malária/diagnóstico , Malária/prevenção & controle , Malária/terapia , Esquistossomose/diagnóstico , Esquistossomose/prevenção & controle , Esquistossomose/terapia , Tripanossomíase Africana/diagnóstico , Tripanossomíase Africana/prevenção & controle , Tripanossomíase Africana/terapiaRESUMO
Hexadecylphosphocholine (miltefosine), a membrane-active alkylphospholipid, may be the first effective oral agent for visceral leishmaniasis, an intracellular protozoal infection of tissue macrophages. In vitro, miltefosine stimulates T cells and macrophages to respond to and secrete activating cytokines, including interferon (IFN)-gamma, and enhances macrophage production of microbicidal reactive nitrogen and oxygen intermediates (RNIs and ROIs, respectively). To determine whether these effects mediate miltefosine's in vivo leishmanicidal efficacy, genetically deficient mice were infected with Leishmania donovani. Intracellular visceral killing was retained in mice lacking or deficient in T cells, endogenous IFN-gamma, and macrophage generation of leishmanicidal RNIs and ROIs. Although mutant mice responded to miltefosine in the absence of tissue granulomas, treatment enhanced granuloma assembly in normal animals. These results suggest that miltefosine's visceral leishmanicidal effect does not require host T cell-dependent or activated macrophage-mediated mechanisms; thus, this agent may potentially be useful in treating T cell-deficient patients with kala-azar.
Assuntos
Antiprotozoários/uso terapêutico , Leishmaniose Visceral/tratamento farmacológico , Ativação de Macrófagos/imunologia , Fosforilcolina/análogos & derivados , Linfócitos T/imunologia , Animais , Leishmania donovani/efeitos dos fármacos , Leishmania donovani/imunologia , Leishmaniose Visceral/imunologia , Camundongos , Fosforilcolina/uso terapêuticoRESUMO
In experimental visceral leishmaniasis, in which the tissue macrophage is the target, in vivo responsiveness to conventional chemotherapy (pentavalent antimony [Sb]) requires a T-cell-dependent mechanism. To determine if this mechanism involves gamma interferon (IFN-gamma)-induced activation and/or specific IFN-gamma-regulated macrophage leishmanicidal mechanisms (generation of reactive nitrogen or oxygen intermediates, we treated gene-deficient mice infected with Leishmania donovani. In IFN-gamma gene knockout (GKO) mice, Sb inhibited but did not kill intracellular L. donovani (2% killing versus 76% in controls). Sb was active (>94% killing), however, in both inducible nitric oxide synthase (iNOS) knockout (KO) and respiratory burst (phagocyte oxidase)-deficient chronic granulomatous disease (X-CGD) mice. Sb's efficacy was also maintained in doubly deficient animals (X-CGD mice treated with an iNOS inhibitor). In contrast to Sb, amphotericin B (AmB) induced high-level killing in GKO mice; AmB was also fully active in iNOS KO and X-CGD animals. Although resolution of L. donovani infection requires iNOS, residual visceral infection remained largely suppressed in iNOS KO mice treated with Sb or AmB. These results indicate that endogenous IFN-gamma regulates the leishmanicidal response to Sb and achieves this effect via a pathway unrelated to the macrophage's primary microbicidal mechanisms. The role of IFN-gamma is selective, since it is not a cofactor in the response to AmB. Treatment with either Sb or AmB permits an iNOS-independent mechanism to emerge and control residual intracellular L. donovani infection.
Assuntos
Interferon gama/imunologia , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/imunologia , Macrófagos/imunologia , Anfotericina B/uso terapêutico , Animais , Antimônio/uso terapêutico , Antiprotozoários/uso terapêutico , Modelos Animais de Doenças , Inibidores Enzimáticos/farmacologia , Feminino , Doença Granulomatosa Crônica/genética , Doença Granulomatosa Crônica/imunologia , Guanidinas/farmacologia , Interferon gama/deficiência , Interferon gama/genética , Leishmaniose Visceral/patologia , Fígado/parasitologia , Fígado/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/deficiência , Óxido Nítrico Sintase/genética , Óxido Nítrico Sintase Tipo IIAssuntos
Malária Falciparum/complicações , Edema Pulmonar/etiologia , Adulto , Animais , Antimaláricos/uso terapêutico , Feminino , Humanos , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/isolamento & purificação , Edema Pulmonar/diagnóstico por imagem , Edema Pulmonar/terapia , RadiografiaRESUMO
Idiopathic CD4 T lymphocytopenia (ICL) is an unusual immune defect in which there is an unexplained deficit of CD4 T cells, leading to fungal, parasitic or other serious opportunistic infections. Current treatment efforts are directed at eliminating infections. Here we describe the use of a novel treatment, subcutaneous polyethylene glycol (PEG)-IL-2 injections, in a woman with this disorder, who had chronic severe mycobacterial disease which led to repeated hospitalizations, and advancing respiratory insufficiency. For this patient, PEG-IL-2, 50 000 U/m2, has been given by weekly subcutaneous injections for 5.5 years. This treatment has resulted in marked (and still continuing) long-term immunological improvement with normalized T cell functions and increased CD4 cell numbers. She has had substantial clinical improvement with clearing of mycobacterial disease, reducing hospitalizations and improved lung functions. The improvement seen in this patient suggests that low-dose IL-2 is a safe and practical therapy, which might be useful in other subjects with this potentially serious immune defect.
Assuntos
Linfócitos T CD4-Positivos/efeitos dos fármacos , Interleucina-2/análogos & derivados , Linfopenia/terapia , Idoso , Feminino , Humanos , Interleucina-2/uso terapêutico , Ativação Linfocitária , PolietilenoglicóisRESUMO
To determine the relative contributions of respiratory burst-derived reactive oxygen intermediates (ROI) versus reactive nitrogen intermediates (RNI) to macrophage-mediated intracellular host defense, mice genetically deficient in these mechanisms were challenged with Leishmania donovani, a protozoan that selectively parasitizes visceral tissue macrophages. During the early stage of liver infection at wk 2, both respiratory burst-deficient gp91(phox)-/- (X-linked chronic granulomatous disease [X-CGD]) mice and inducible nitric oxide synthase (iNOS) knockout (KO) mice displayed comparably increased susceptibility. Thereafter, infection was unrestrained in mice lacking iNOS but was fully controlled in X-CGD mice. Mononuclear cell influx into infected liver foci in X-CGD and iNOS KO mice was also overtly impaired at wk 2. However, granuloma assembly in parasitized tissue eventually developed in both hosts but with divergent effects: mature granulomas were functionally active (leishmanicidal) in X-CGD mice but inert in iNOS-deficient animals. These results suggest that (a) ROI and RNI probably act together in the early stage of intracellular infection to regulate both tissue recruitment of mononuclear inflammatory cells and the initial extent of microbial replication, (b) RNI alone are necessary and sufficient for eventual control of visceral infection, and (c) although mature granulomas have traditionally been associated with control of such infections, these structures fail to limit intracellular parasite replication in the absence of iNOS.
Assuntos
Doença Granulomatosa Crônica/imunologia , Leishmania donovani/imunologia , Leishmaniose Visceral/imunologia , Ativação de Macrófagos/fisiologia , Macrófagos/fisiologia , Glicoproteínas de Membrana/fisiologia , NADPH Oxidases/fisiologia , Óxido Nítrico Sintase/fisiologia , Óxido Nítrico/imunologia , Espécies Reativas de Oxigênio/imunologia , Animais , Predisposição Genética para Doença , Granuloma/etiologia , Granuloma/imunologia , Granuloma/parasitologia , Granuloma/patologia , Doença Granulomatosa Crônica/complicações , Doença Granulomatosa Crônica/genética , Leishmaniose Visceral/complicações , Fígado/parasitologia , Macrófagos/parasitologia , Glicoproteínas de Membrana/deficiência , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , NADPH Oxidase 2 , NADPH Oxidases/deficiência , NADPH Oxidases/genética , Óxido Nítrico Sintase/deficiência , Óxido Nítrico Sintase/genética , Óxido Nítrico Sintase Tipo IIRESUMO
Fifty-eight Indian patients with visceral leishmaniasis who did not respond or relapsed after 30 days of consecutive sodium stibogluconate therapy were randomised to treatment with amphotericin B lipid complex (ABLC) using a total dose of 7.5 or 10 mg/kg. Treatment induced a prompt clinical response in all patients with resolution of fever and regression in spleen size. Fever and chills developed during ABLC infusion, but it diminished with successive infusions. Fourteen days after treatment, 26 of 28 (93%) patients in the 7.5 mg/kg group and all 30 (100%) in the 10 mg/kg group had splenic aspirate parasite density scores of 0 and were considered apparent clinical and parasitologic responders. Four and three patients in the 7.5 and 10 mg/kg groups respectively relapsed during six months of followup; thus, overall 22 of 28 (79%) patients treated with 7.5 mg/kg and 27 of 30 (90%) treated with 10 mg/kg were definitive cures. All initial non-responders and relapses were retreated successfully with higher dose of ABLC. These results confirm the efficacy of short-course ABLC therapy for antimony-unresponsive Indian patients with visceral leishmaniasis. Since treatment with a total dose of 7.5 mg/kg did not appear to increase efficacy (79% vs. 84% induced by 5 mg/kg in a prior study), initial treatment with a total dose of 5 mg/kg followed by retreatment of any non-responders represents a potentially less costly approach in patients who fail antimony therapy. Though high cure rates are achieved with > or = 10 mg/kg total dose of ABLC, treatment using lower doses with retreatment of non-responders or relapses with higher dose can result in considerable savings.